当前位置: X-MOL 学术Sci. Transl. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Science Translational Medicine ( IF 15.8 ) Pub Date : 2020-01-01 , DOI: 10.1126/scitranslmed.aax7533
Huiyan Luo 1 , Qi Zhao 1 , Wei Wei 1 , Lianghong Zheng 2 , Shaohua Yi 3 , Gen Li 4 , Wenqiu Wang 5 , Hui Sheng 1 , Hengying Pu 1 , Haiyu Mo 1 , Zhixiang Zuo 1 , Zexian Liu 1 , Chaofeng Li 1 , Chuanbo Xie 1 , Zhaolei Zeng 1 , Weimin Li 6 , Xiaoke Hao 7 , Yuying Liu 1 , Sumei Cao 1 , Wanli Liu 1 , Sarah Gibson 4 , Kang Zhang 6, 8 , Guoliang Xu 1 , Rui-Hua Xu 1
Affiliation  

Circulating tumor DNA (ctDNA) has emerged as a useful diagnostic and prognostic biomarker in many cancers. Here, we conducted a study to investigate the potential use of ctDNA methylation markers for the diagnosis and prognostication of colorectal cancer (CRC) and used a prospective cohort to validate their effectiveness in screening patients at high risk of CRC. We first identified CRC-specific methylation signatures by comparing CRC tissues to normal blood leukocytes. Then, we applied a machine learning algorithm to develop a predictive diagnostic and a prognostic model using cell-free DNA (cfDNA) samples from a cohort of 801 patients with CRC and 1021 normal controls. The obtained diagnostic prediction model discriminated patients with CRC from normal controls with high accuracy (area under curve = 0.96). The prognostic prediction model also effectively predicted the prognosis and survival of patients with CRC (P < 0.001). In addition, we generated a ctDNA-based molecular classification of CRC using an unsupervised clustering method and obtained two subgroups of patients with CRC with significantly different overall survival (P = 0.011 in validation cohort). Last, we found that a single ctDNA methylation marker, cg10673833, could yield high sensitivity (89.7%) and specificity (86.8%) for detection of CRC and precancerous lesions in a high-risk population of 1493 participants in a prospective cohort study. Together, our findings showed the value of ctDNA methylation markers in the diagnosis, surveillance, and prognosis of CRC.

中文翻译:

循环中的肿瘤DNA甲基化谱可实现早期诊断,预后预测和筛查大肠癌。

循环肿瘤DNA(ctDNA)已成为许多癌症中有用的诊断和预后生物标志物。在这里,我们进行了一项研究,以调查ctDNA甲基化标记物在大肠癌(CRC)诊断和预后中的潜在用途,并使用前瞻性队列研究来验证其在筛查CRC高危患者中的有效性。我们首先通过将CRC组织与正常血液白细胞进行比较来确定CRC特异性甲基化特征。然后,我们应用机器学习算法,使用来自801名CRC患者和1021名正常对照人群的无细胞DNA(cfDNA)样本,开发了预测性诊断和预后模型。所获得的诊断预测模型可将CRC患者与正常对照高精度地区分(曲线下面积= 0.96)。预后预测模型还可以有效地预测CRC患者的预后和生存率(P <0.001)。此外,我们使用无监督聚类方法生成了基于ctDNA的CRC分子分类,并获得了两个亚组的CRC患者,这些患者的总生存期存在显着差异(在验证队列中P = 0.011)。最后,我们在一项前瞻性队列研究中发现,单个ctDNA甲基化标记物cg10673833在检测1493名高危人群中的CRC和癌前病变方面可产生高灵敏度(89.7%)和特异性(86.8%)。在一起,我们的研究结果表明ctDNA甲基化标记物在CRC的诊断,监测和预后中的价值。我们使用无监督聚类方法生成了基于ctDNA的CRC分子分类,并获得了两个亚组的CRC患者,这些患者的总生存期存在显着差异(在验证队列中P = 0.011)。最后,我们在一项前瞻性队列研究中发现,单个ctDNA甲基化标记物cg10673833在检测1493名高危人群中的CRC和癌前病变方面可产生高灵敏度(89.7%)和特异性(86.8%)。在一起,我们的研究结果表明ctDNA甲基化标记物在CRC的诊断,监测和预后中的价值。我们使用无监督聚类方法生成了基于ctDNA的CRC分子分类,并获得了两个亚组的CRC患者,这些患者的总生存期存在显着差异(在验证队列中P = 0.011)。最后,我们在一项前瞻性队列研究中发现,单个ctDNA甲基化标记物cg10673833在检测1493名高危人群中的CRC和癌前病变方面可产生高灵敏度(89.7%)和特异性(86.8%)。在一起,我们的研究结果表明ctDNA甲基化标记物在CRC的诊断,监测和预后中的价值。cg10673833,在一项前瞻性队列研究中,对1493名高风险人群的CRC和癌前病变的检测具有很高的灵敏度(89.7%)和特异性(86.8%)。在一起,我们的研究结果表明ctDNA甲基化标记物在CRC的诊断,监测和预后中的价值。cg10673833,在一项前瞻性队列研究中,对1493名高风险人群的CRC和癌前病变的检测具有很高的灵敏度(89.7%)和特异性(86.8%)。在一起,我们的研究结果表明ctDNA甲基化标记物在CRC的诊断,监测和预后中的价值。
更新日期:2020-01-02
down
wechat
bug